ABSTRACT:

The use of HAART for the treatment of HIV/AIDS infection, despite its success, has been reported to be accompanied by increased number of adverse drug reactions (ADRs) for which some risk factors such as age, gender, co-morbidities have been implicated. The association between alcohol consumption, herbal drug intake and use of co-trimoxazole and ADRs to HAART has not been documented much. The main objective of this study is to determine the association between alcohol consumption, herbal drug intake, use of co-trimoxazole and presentation of ADRs to HAART in HIV/AIDS patients in Makurdi where there’s high HIV infection, alcohol consumption and herbal use. It was a combination of prospective and retrospective study at FMC, Makurdi. We used clinical records of the patients and questionnaires for patients enrolled from January to October, 2019 and followed up for six months. The biodata, drug history including herbal medications and social life (use of alcohol) history were retrieved. A total number of three hundred and three (303) patients were recruited during the study period out of which two hundred and ten (210) patients were used. From a total of 210 patients, 144 (68. 6%) were females while sixty-six, 66 (31.4 %) were males. Of these, only 68(32.4%) patients took alcohol while 89 (42.4%) patients used herbal medications together with HAART regimen and 185(88.1) were on cotrimoxazole prophylaxis. 22 patients presented with ADR with peripheral neuropathy and insomnia being the commonest ADRs. 54.5% (majority) of the patients with ADRs took alcohol while 81.8% (majority) of the patients who developed ADRs were actually on herbal medications or co-trimoxazole. The p-value>0.05. Alcohol consumption, herbal medication use and co-trimoxazole prophylaxis in HIV/AIDS positive patients while on ARVs may increase ADRs to ARVs. Thus, HIV/AIDS patients should be
discouraged from use of alcohol and herbal medication while on HAART.

KEYWORDS:

HAART, ADRs, Alcohol, Herbal Medication

REFERENCES :

1) Bhatnagar, S., Sharma, H. and Sharma, V., 2013 “study of adverse effects of anti-retroviral therapy in hiv patients and their association with cd4 cell count”, Asian Journal of Pharmaceutical and Clinical Research, 6(9): 122-123. Available at: 

https://innovareacademics.in/journals/index.php/ajpcr/article/view/580 [Accessed on July 20, 2020].
2) Bhuvana, K., Hema, N., and Sangeetha, O., 2014. A prospective observational study of adverse drug reactions to antiretroviral therapy: type and risk factors in a tertiary care teaching hospital. Int J Basic ClinPharmacol.3 (2): 380-384. 

DOI: 10.5455/2319-2003.ijbcp20140425.
3) Braithwaite, R., Conigliaro, J., Roberts,S., Shechter, S., Schaefer, A., et al. 2007. Estimating the impact of alcohol consumption on survival for HIV- individuals. AIDS Care 19: 459-466. DOI: 10.1080/09540120601095734.
4) Calmy, A., Hirschel, B., Cooper, D. A. and Carr, A., 2009.A new era of antiretroviral drug toxicity.Antiviral Therapy, 14 (2): 165-179. PMID: 19430091.
5) Charles, B., Pedro, C., David, A. C., Sharon, L. W., Christine, K., Bonaventura, C. N., Adriano, L., Margaret, A., J., Dietmar, N., Douglas, M., and Hernan, V., 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the
Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from analysis of combined data from two randomised open-label trials. The Lancet.368 (9534):466-475. 

https://doi.org/10.1016/S0140-6736(06)69154-X.
6) Florence,N., 2011. Detection and Managemen to fAdverse Drug Reactions Related to HIV/AIDS Patients in Kiambu District ,Kenya. A Research Thesis Submitted in Partial Fulfillment of the Requirement for the Degree of Master of Public Health in the School of Health Sciences of Kenya ttaUniversity. Registrationno.157/10723/07
7) Lut, D., Amy, C., Khatija, A., Kawango, A., Johan, L., Saidi, K., Mookho, M., Fredrick, O., Rachel, M., Jacob, O., Lucky, T., Modie, C. M., Paul, M., Mankalimeng, M., Ilse, R., Shumani, E. M., Lisa, S., Haddie, K., Stella, K., Christina, W., Robert, G., Angela, K., Kavita, N., Justin, M., Katrien, F., Jennifer, D., Tania, C., Timothy, D. M., Douglas, T., and FEM-PrEP Study Group.,2012. Preexposure Prophylaxis for HIV Infection among African Women.The New England journal of medicine, 367(5): 411–422. 

https://doi.org/10.1056/NEJMoa1202614.
8) Monera, G., Wolfe,R., Maponga, C., Benet, Z., andGuglielmo, J., 2008.Moringaoleifera leaf extracts inhibit 6-betahydroxylation of testosterone by CYP3A4. J Infect DevCtries. 2:379–83.[PubMed: 19745507].
9) NACA, 2019. National Agency for the Control of AIDS: Future Directions for The HIV/AIDS Response in Nigeria. Revised National HIV and AIDS Strategic Framework 2019-2021.[Accessed on July 31, 2019].
10) Nemaura, T., Dhoro,. M, Nhachi, C., Kadzirange, G., Chonzi, P., 2013. Evaluation of the Prevalence, Progression and Severity of Common Adverse Reactions (Lipodystrophy, CNS, Peripheral Neuropathy, and Hypersensitivity Reactions) Associated with Anti-Retroviral Therapy (ART) and Anti-Tuberculosis Treatment in Outpatients in Zimbabwe. Journal of
AIDS and Clinical Research, 4(4): 203. doi:10.4172/2155-6113.1000203 11) Nyasha, B., Nathan, M., Tinashe, M., Samuel, G., Charles, M., and Gene, M. 2011.The impact of herbal remedies on adverse effects and quality of life in HIV-infected individuals on antiretroviral therapy.J. Infect DevCtries. 2011 Feb 1;
5(1): 48–53. PMCID: PMC3424263 NIHMSID: NIHMS352183 PMID: 21330740.
12) Rabkin, M., El-Sadr, W., Katzenstein, D. A., Mukherjee, J., Masur, H., Mugyenyi, P., Munderi, P. and Darbyshire, J., 2002. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (London, England), 360(9344): 1503–1505. 

https://doi.org/10.1016/S0140- PMID: 12433534.
13) Ramanjireddym, T., and Yitagesu M., 2014. Prevalence of ADRs and Associated Factors of Antiretroviral Treatment on HIV Positive Adults at JUSH.Indian Journal of Pharmacy Practice, Vol . 7, Issue 4. 

14) Schneider, M., Neuman, M., Chersich, M. and Parry, C., 2011. Alcohol and Antiretroviral Therapy – A Lethal Cocktail.J AIDS Clinic Res S1:005.doi:10.4172/2155-6113.S1-005.
15) Sharp, PM., and Hahn, H., 2011.Origins of HIV and the AIDS pandemic. Cold Spring Harbor perspectives in medicine, 1(1), a006841.PMID: 22229120PMCID: PMC3234451

https://doi.org/10.1101/cshperspect.a006841.
16) Tinashe, M., Charles, C. M., Star, K., Qing, M. and Gene, D. M., 2012. The Impact of Herbal Drug Use on Adverse Drug Reaction Profiles of Patients on Antiretroviral Therapy in Zimbabwe.AIDS Res Treat. 2012:
434171. doi: 10.1155/2012/434171PMCID:PMC3313558.
17) UNAIDS, 2019. Press Release: New survey results indicate that Nigeria has an HIV prevalence of1.4%. 

https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190314_nigeria
[Accessed on March 15, 2020].
18) WHO, 2002.The use of antiretroviral therapy: a simplified approach for resource-constrained countries:
World Health Organization.
https://apps.who.int/iris/bitstream/handle/10665/206000/B0184.pdf?sequence=1&isAllowed=y [Accessed on August 6,
2019].
19) WHO, 2013.Surveillance of antiretroviral drug toxicity during pregnancy and breastfeeding.
GenevaWorldHealthOrganization. http://apps.who.int/iris/handle/10665/91768?mode=full. [Accessed on June 9,
2015].